Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00093080
Other study ID # 8669-018
Secondary ID AP23573-04-20220
Status Completed
Phase Phase 2
First received September 30, 2004
Last updated February 12, 2015
Start date October 2004
Est. completion date November 2008

Study information

Verified date February 2015
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.


Recruitment information / eligibility

Status Completed
Enrollment 216
Est. completion date November 2008
Est. primary completion date November 2008
Accepts healthy volunteers No
Gender Both
Age group 15 Years and older
Eligibility Inclusion Criteria:

- Patients =15 years of age with metastatic and/or unresectable sarcomas of the following histological subgroups: Bone sarcomas, such as osteosarcoma and Ewings sarcoma; Leiomyosarcoma; Liposarcomas; Any other soft tissue sarcoma except gastrointestinal stromal tumors (GIST). Patients with well-differentiated liposarcoma or desmoid tumors must have demonstrated progressive disease within the previous 6 months

- Presence of at least one measurable lesion that: Can be accurately measured in at least one dimension with longest diameter =20 mm using conventional techniques or =10 mm with spiral computerized tomography (CT) scan (or otherwise at least twice the reconstruction interval for CT or magnetic resonance imaging [MRI] scans)

- Eastern Cooperative Oncology Group (ECOG) performance status =1

- Minimum life expectancy of 3 months

- Adequate renal and hepatic function, as specified in the protocol

- Adequate bone marrow function, as specified in the protocol

- Serum cholesterol <350 mg/dL and triglycerides < 400 mg/dL

- Male and female patients who are not surgically sterile or postmenopausal must agree to use reliable methods of birth control for the duration of the study until 30 days after the last dose of study drug

- Able to understand and give written informed consent

Exclusion Criteria:

- Women who are pregnant or lactating

- Presence of brain metastases

- Prior therapy with rapamycin, rapamycin analogues or tacrolimus

- Prior anticancer treatment (chemotherapy, radiotherapy, hormonal, immunotherapy, biological response modifiers, signal transduction inhibitors, etc) within 4 weeks prior to the first dose of ridaforolimus

- Ongoing toxicity associated with prior anticancer therapy (except peripheral neuropathy of = grade 1 by National Cancer Institute (NCI) toxicity criteria)

- Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ)

- Known or suspected hypersensitivity to drugs formulated with polysorbate 80 (Tween) or any other excipient contained in the study drug

- Known Grade 3 or 4 hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin)

- Significant uncontrolled cardiovascular disease

- Active infection requiring systemic therapy

- Known human immunodeficiency virus (HIV) infection

- Treatment with any investigational agent within 4 weeks prior to the first dose of ridaforolimus

- Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids at stable doses for 2 weeks prior to first planned dose of study drug

- Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of ridaforolimus

- Presence of any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluating the safety of the study drug

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
ridaforolimus
12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp. Ariad Pharmaceuticals

References & Publications (1)

Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients w — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with Clinical Benefit Response (CBR) Using Response Criteria in Solid Tumors (RECIST) Day 1 up to 4 years or discontinuation from study Yes
Secondary Time to Tumor Progression Day 1 up to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years) No
Secondary Progression Free Survival Day 1 to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years) No
Secondary Overall Survival Day 1 to the date of death, or the date of last contact (up to 4 years) No
Secondary Duration of Response Day 1 up to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years) No
Secondary Number of participants experiencing adverse events From first dose up to 30 days after last dose (up to 1 year) Yes
Secondary Number of participants who discontinued study drug due to adverse events From first dose up to the last dose (up to 1 year) Yes
Secondary Mean ridaforolimus blood levels within 5 minutes post intravenous infusion Day 1 and Day 5 of Cycle 1 No
See also
  Status Clinical Trial Phase
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Not yet recruiting NCT05515068 - Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Completed NCT02383901 - A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX N/A
Active, not recruiting NCT01758666 - A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy N/A
Completed NCT01674101 - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy N/A
Completed NCT01615640 - Diffusion Study on Patients With Osteosarcoma
Completed NCT00520936 - A Study of Pemetrexed in Children With Recurrent Cancer Phase 2
Completed NCT00523419 - Chemotherapy for Patients With Osteosarcoma Phase 2
Completed NCT00132158 - ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase 1
Not yet recruiting NCT04319874 - Phase II Clinical Trial Scheme of Ganoderma Lucidum Spore Powder for Postoperative Chemotherapy of Osteosarcoma Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Recruiting NCT05642455 - SPEARHEAD-3 Pediatric Study Phase 1/Phase 2
Recruiting NCT06117878 - Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma Early Phase 1
Not yet recruiting NCT04316091 - A Phase I Clinical Trial of Neoadjuvant Chemotherapy With/Without SPIONs/SMF for Patients With Osteosarcoma Phase 1
Recruiting NCT03932058 - Proteomics Research of Osteosarcoma
Withdrawn NCT01236586 - RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Completed NCT00743496 - A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma Phase 1
Recruiting NCT04040205 - Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Phase 2
Recruiting NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT03628209 - Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Phase 1/Phase 2